New therapies for cytomegalovirus retinitis

International Ophthalmology Clinics

Volumn 36, Issue 2, 1996, Pages 1-9

  Schwartz, Daniel M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; FOSCARNET; GANCICLOVIR;

ANTIVIRAL ACTIVITY; BLINDNESS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; INTRAVITREAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RETINITIS; REVIEW;

EID: 0029960631     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004397-199603620-00003     Document Type: Review

References (35)

1. Freeman W, Lerner C, Mines M, et al. A prospective study of the ophthalmologic findings in the acquired immune deficiency syndrome. Am J Ophthalmol 1984;97:133-142
2. Palestine A, Rodrigues M, Macher A, et al. Ophthalmic involvement in acquired immunodeficiency syndrome. Ophthalmology 1984;91:1092-1099
3. Jabs D, Green W, Fox R, et al. Ocular manifestations of acquired immune deficiency syndrome. Ophthalmology 1989;96:1092-1099
4. Jabs DA, Enger C, Bartlett JG. Cytomegalovirus retinitis and acquired immune deficiency syndrome. Arch Ophthalmol 1989;96:75-80
5. Kuppermann BD, Petty JG, Richman DD, et al. Correlation between CD4+ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus- related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am J Ophthalmol 1993;115:575-582
6. Studies of the Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992;326:213-220
7. Henry K, Cantrill H, Fletcher C, et al. Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. Am J Ophthalmol 1987;103:17-23
8. Buchi ER, Fitting PL, Michel AE. Long-term intravitreal ganciclovir for cytomegalovirus retinitis in a patient with AIDS: case report. Arch Ophthalmol 1988;106:1439-1450
9. Engstrom R Jr, Holland G. Perspective: local therapy for cytomegalovirus retinopathy. Am J Ophthalmol 1995;120:376-385
10. Diaz-Llopis M, Chipont E, Sanchez S, et al. Intravitreal foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome. Am J Ophthalmol 1992;114:742-747
11. Diaz-Llopis M, Espana E, Munoz G, et al. High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS. Br J Ophthalmol 1994;78:120-124
12. Young SH, Morlet N, Heery S, et al. High close intravitreal ganciclovir in the treatment of cytomegalovirus retinitis. Med J Aust 1992;157:370-373
13. Morlet N, Young S, Naidoo D, et al. High dose intravitreal ganciclovir for CMV retinitis; a shelf life and cost comparison study. Br J Ophthalmol 1995;79:753-755
14. Morlet N, Young S, Naidoo D, et al. High dose intravitreal ganciclovir injection provides a prolonged therapeutic intraocular concentration. Br J Ophthalmol 1996;80:214-216
15. Cantrill HL, Henry K, Melroe NH, et al. Treatment of cytomegalovirus retinitis with intravitreal ganciclovir; long-term results. Ophthalmology 1989;96:367-374
16. Heinemann MH. Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy. Arch Ophthalmol 1989;107:1767-1772
17. Cochereau-Massin I, Le Hoang P, Lautier-Frau M, et al. Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 1991;98:1349-1353
18. Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. Arch Ophthalmol 1994;112:1531-1539
19. Smith TJ, Pearson PA, Blandford DL, et al. Intravitreal sustained-release ganciclovir. Arch Ophthalmol 1992;110:255-258
20. Ashton P, Blandford DL, Pearson PA, et al. Review: implants. J Ocul Pharmacol 1994;10:691-701
21. Sanborn GE, Anand R, Torti R, et al. Sustained release ganciclovir therapy for treatment of cytomegalovirus retinitis: use of an intravitreal device. Arch Ophthalmol 1992;110:188-195
22. Morley MG, Duker JS, Ashton P, et al. Replacing ganciclovir implants. Ophthalmology 1995:102:388-392
23. Jabs DA, Enger C, Haller J, deBustros S. Retinal detachments in patients with cytomegalovirus retinitis. Arch Ophthalmol 1991;109:794-799
24. Freeman WR, Friedberg DN, Berry C, et al. Risk factors for development of rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis. Am J Ophthalmol 1993;116:713-720
25. The Chiron Ganciclovir Implant Study Group, Chiron Vision Corporation, Irvine, CA. A randomized controlled multicenter clinical trial of a sustained release intraocular ganciclovir implant in AIDS patients with CMV retinitis. Second National Conference on Human Retroviruses and Related Infections: Official Abstract Form 1996;LB16
26. Anderson RD, Griffy KG, Jung D, et al. Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus and cytomegalovirus-seropositive patients. Clin Ther 1995;17:425-432
27. Spector SA, Busch DF, Follansbee S, et al. Pharmacokinetic, safety and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. J Infect Dis 1995;171:143-147
28. Plotkin SA, Drew WL, Felsenstein D, Hirsch MS. Sensitivity of clinical isolates of human cytomegalovirus to 9-(1,3-dihydroxy-2-propoxymethyl) guanine. J Infect Dis 1985;152:833-834
29. Drew WL, Ives D, Lalezari JP, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995;333:615-620
30. Holland GN, Tufail A. New therapies for cytomegalovirus retinitis. N Engl J Med 1995;333:658-659
31. Hitchcock MJM, Jaffe HS, Matin JS, Stagg RJ. Cidofovir, a new agent with potent antiherpesvirus activity. Antiviral Chem Chemother 1996;7(3):115-127
32. Cundy K, Petty BG, Flaherty J, et al. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1995;39:1247-1252
33. Cherrington JM, Miner R, Hitchcock MJM, et al. Susceptibility of human cytomegalovirus to cidofovir is unchanged after limited in vivo exposure to various clinical regimens of drug. J Infect Dis 1996;173:987-992
34. Lalezari JP, Drew WL, Glutzer E, et al. (s)-1-[3-Hydroxy-2-(phosphonylmethoxy) propyl] cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J Infect Dis 1995;171:788-796
35. Kisch LS, Arevalo JF, Chavez de la Paz E, et al. Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophthalmology 1995;102:533-543